AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35274344
Drug: Advice on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice on oral health care (Control group)
Trial: 34936272
Drug: Wangbuliuxing decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wangbuliuxing decoction (oral administration, twice a day for 7 days) combined with massage at breast and acupoint (Zhongfu [LU 1], Yunmen [LU 2], Danzhong [CV 17], 2 min per acupoint, twice a day for 7 days)
Trial: 35002228
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of BMMC and ADSC
Trial: 32660542
Drug: Moxidectin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (24 μg/kg) for four or six monthly doses
Trial: 32660542
Drug: Heartgard® Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heartgard® Plus (ivermectin/pyrantel) for six monthly doses
Trial: 32660542
Drug: Interceptor® Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interceptor® Plus (milbemycin oxime/praziquantel) for six monthly doses
Trial: 33180306
Drug: One-level RDL
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-level RDL reductions achieved by 84% of patients at the end of treatment; 84.9% maintained reduction at 3-year follow-up.
Trial: 33180306
Drug: Two-level RDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-level RDL reductions achieved by 68% of patients at the end of treatment; 77.7% maintained reduction at 3-year follow-up.
Trial: 35617452
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel applied every night (control)
Trial: 34471992
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg every 4 weeks (Q4W)
Trial: 34471992
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (weekly until Week 4, then Q4W)
Trial: 33290813
Drug: Heparin locking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin locking
Trial: 33290813
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (SQH) 7,500 units TID
Trial: 33290813
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (SQH) 5,000 units
Trial: 33290813
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (SQH) 7,500 units vs 5,000 units
Trial: 34842135
Drug: Antidepressant continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant continuation (maintenance group)
Trial: 34842135
Drug: Antidepressant discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant discontinuation (discontinuation group)
Trial: 34008144
Drug: Colchicine and
RxNorm normalized name: colchicine and probenecid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs)
Trial: 32892655
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg tablet (formulation 1)
Trial: 32892655
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg tablet (formulation 2)
Trial: 35667420
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with hyaluronic acid gel
Trial: 35972817
Drug: Ribociclib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (400 mg) combined with weekly carboplatin and paclitaxel chemotherapy followed by ribociclib maintenance
Trial: 36197167
Drug: Humidified low-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified low-flow oxygen therapy
Trial: 36197167
Drug: Nonhumidified low-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhumidified low-flow oxygen therapy
Trial: 34781363
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 or 2 g/kg
Trial: 32114905
Drug: Therapy Component
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy Component Checklist (TCC)
Trial: 35435472
Drug: veliparib 400
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: veliparib 400 mg BID
Trial: 35435472
Drug: veliparib 50-500
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: veliparib 50-500 mg BID
Trial: 34196106
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic preconditioning (RIPC) - 3 × 5 min administration of 200 mmHg sphygmomanometer on the arm (n=31)
Trial: 34196106
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n=29)
Trial: 33152965
Drug: Fentanyl 1–2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1–2 μg/kg
Trial: 33152965
Drug: Fentanyl 6–7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 6–7 μg/kg
Trial: 36052684
Drug: ACE-inhibitor+thiazide
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor+thiazide
Trial: 36052684
Drug: CCB+ACE-inhibitor
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB+ACE-inhibitor
Trial: 35482348
Drug: Primary RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary RT (60 Gy of RT with concurrent weekly cisplatin in node-positive patients)
Trial: 35482348
Drug: TOS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOS and neck dissection (ND) with adjuvant reduced-dose RT depending on pathologic findings
Trial: 34488362
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (CT) - TESSYS technique under spinal endoscopy + drug therapy (coenzyme A, adenosine triphosphate, 10% glucose injection, 10% potassium chloride, vitamin B6, vitamin B12, dexamethasone, 20% mannitol, traditional Chinese medicine)
Trial: 34488362
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (CT)
Trial: 33561312
Drug: Panitumumab 6
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg
Trial: 33561312
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg
Trial: 33106183
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Interferon beta-1a + lopinavir/ritonavir (Kaletra)
Trial: 33106183
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Interferon beta-1a + lopinavir/ritonavir (Kaletra)
Trial: 32339169
Drug: Capacitive resistive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive resistive radiofrequency therapy (RF)
Trial: 35395957
Drug: Hydroxychloroquine, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine, twice daily for 14 days
Trial: 35395957
Drug: Lopinavir/ritonavir, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir, twice daily for 14 days
Trial: 36271391
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine drug treatment: NSAIDs & Anti TNF)
Trial: 33515503
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice a day orally for six cycles of 28 days or until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Trial: 35059823
Drug: Arthroscopic debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic debridement of dorsal capsule injuries during primary surgery
Trial: 35059823
Drug: No debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No debridement of dorsal capsule injuries during primary surgery
Trial: 32196954
Drug: Levocetirizine oral
RxNorm normalized name: levocetirizine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine oral disintegrating tablet (ODT) 5 mg
Trial: 32196954
Drug: Levocetirizine immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine immediate-release tablet (IRT) 5 mg
Trial: 35872697
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus intensive exercise diet therapy
Trial: 36544634
Drug: ACP gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP gel
Trial: 33745372
Drug: Neuroanimation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroanimation therapy (NAT)
Trial: 33745372
Drug: Neuroanimation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroanimation therapy (NAT) and Conventional occupational therapy (COT) combined
Trial: 35357753
Drug: 30% metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% metformin cream
Trial: 35357753
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream (Kligman's formula)
Trial: 34217079
Drug: Glyphosate 7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate 7.2 g a.e. ha−1 in winter season
Trial: 34217079
Drug: Glyphosate 36.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate 36.0 g a.e. ha−1 in winter season
Trial: 34217079
Drug: Glyphosate 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate 1.8 g a.e. ha−1 in winter season
Trial: 34217079
Drug: Glyphosate 12
RxNorm normalized name: GLYPHOSATE
DrugBank: Glyphosate (DB04539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyphosate 12 g a.e. ha−1 in wet season
Trial: 33734452
Drug: THY1773 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THY1773 (10 mg/day to 110 mg/day)
Trial: 33734452
Drug: THY1773 (TS-121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THY1773 (TS-121 capsule)
Trial: 33870705
Drug: Oral Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Anticoagulation (OAC)
Trial: 32772571
Drug: Antiplatelet Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet Therapy (APT)
Trial: 2004897541
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (only regular therapy)
Trial: 34538275
Drug: ACT-guided heparinization
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-guided heparinization (100 IU/kg bolus of heparin with ACT measurements)
Trial: 34538275
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU of heparin (no ACT measurements)
Trial: 36017827
Drug: RID-TDS (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RID-TDS (twice weekly)
Trial: 36017827
Drug: Exelon® (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exelon® (once daily)
Trial: 32206785
Drug: Prolyl-hydroxylase domain
RxNorm normalized name: antihemophilic factor, porcine B-domain truncated recombinant Injection [Obizur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolyl-hydroxylase domain (PHD) inhibitors
Trial: 33148203
Drug: Randomised controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised controlled trial of first-line intravenous iron
Trial: 32450733
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol and desflurane
Trial: 33561968
Drug: Lacto-ovo-vegetarian diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacto-ovo-vegetarian diet (VD; 65 g/day protein)
Trial: 33561968
Drug: Western-type diet
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western-type diet (WD; 95 g/day protein)
Trial: 33561968
Drug: Mixed diet
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed diet (MD; 65 g/day protein)
Trial: 35527114
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution combined with orthokeratology (OK)
Trial: 35527114
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution with spectacles
Trial: 32940765
Drug: Clotrimazole (CT)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole (CT) 100 mg
Trial: 32940765
Drug: Dequalinium chloride
RxNorm normalized name: dequalinium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dequalinium chloride (DQC) 10 mg
Trial: 36217643
Drug: SmearOFF as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SmearOFF as the final irrigant + 2% Chlorhexidine gel as intracanal medicament (n=14)
Trial: 35652260
Drug: Letrozole (LZ)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LZ) 5 mg
Trial: 34976331
Drug: Active initiation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active initiation of secondary prevention therapy (aspirin, beta-blockers, statins, ACEI/ARBs)
Trial: 34976331
Drug: Passive continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive continuation of prior medication (aspirin, beta-blockers, statins)
Trial: 32652910
Drug: Non-drug users
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug users (N-MMT group)
Trial: 35093230
Drug: Inactivated whole‐virion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole‐virion SARS‐CoV‐2 vaccine (CoronaVac)
Trial: 34733813
Drug: Yoga group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga group (N = 49) attended a yoga course consisting of 10 sessions (1.5 h each) on a weekly basis
Trial: 35427491
Drug: Hypothetical gonorrhoea
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical gonorrhoea vaccine
Trial: 32243716
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ketorolac tromethamine prior to local anaesthesia with 2% lignocaine and 1:80,000 adrenaline
Trial: 32243716
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ketorolac tromethamine prior to local anaesthesia with 4% articaine and 1:100,000 adrenaline
Trial: 32888192
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CII) of enoxaparin
Trial: 32888192
Drug: Standard subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subcutaneous bolus (SCB) of enoxaparin
Trial: 32216731
Drug: Pelvic intensity-modulated
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intensity-modulated radiation therapy (IMRT)
Trial: 36490309
Drug: metformin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin combined with neoadjuvant chemotherapy and trastuzumab
Trial: 36490309
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy and trastuzumab without metformin
Trial: 32729631
Drug: Pimavanserin (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin (34 mg)
Trial: 35273972
Drug: Alginate drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate drink (one bottle twice a day for 8 weeks after A-FMT)
Trial: 32183874
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual, wait-list control group
Trial: 33334157
Drug: Pathway 3
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathway 3 (community mental health stepped care): CHWs screen patients and deliver behavioral EBIs in the community and refer medication management cases to PCPs in clinics.
Trial: 33675081
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (70 g/280 kcal) drink
Trial: 36760537
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (ESWT) applied once a week for 5 weeks, combined with a 5-week advanced rehabilitation training program (30 minutes/session, 5 times/week) starting at 3 months postoperatively
Trial: 33196155
Drug: Warfarin (dose-adjusted,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted, target INR 2.0 to 3.0)
Trial: 35781888
Drug: 3-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 3 days, followed by placebo for 4 days)
Trial: 35781888
Drug: 7-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day antibiotic protocol (500 mg amoxicillin and metronidazole 3 times a day for 7 days)
Trial: 35485332
Drug: JNJ-64794964 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64794964 0.2 mg
Trial: 35485332
Drug: JNJ-64794964 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64794964 0.6 mg
Trial: 35485332
Drug: JNJ-64794964 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64794964 1.25 mg
Trial: 35485332
Drug: JNJ-64794964 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64794964 1.8 mg
Trial: 35485332
Drug: JNJ-64794964 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64794964 1.25 mg (MD phase)
Trial: 35810356
Drug: rh‐bFGF nasal‐spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh‐bFGF nasal‐spray
Trial: 35810356
Drug: rh‐bFGF nasal‐spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh‐bFGF nasal‐spray and drop
Trial: 36335297
Drug: 100-μg dexmedetomidine
RxNorm normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Trial: 36335297
Drug: 50-μg dexmedetomidine
RxNorm normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50-μg dexmedetomidine plus 35-mL 0.5% levobupivacaine
Trial: 36335297
Drug: 35-mL 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35-mL 0.5% levobupivacaine plus normal saline
Trial: 33991221
Drug: Intravaginal estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal estriol 0.03 mg plus Lactobacillus acidophilus 100 million viable cell vaginal tablets
Trial: 32668323
Drug: LUS-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUS-guided treatment
Trial: 33501671
Drug: Nusinersen (12‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen (12‐mg scaled equivalent dose)
Trial: 34489756
Drug: LIFEwithIBD intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LIFEwithIBD intervention + Treatment As Usual (TAU)
Trial: 32266682
Drug: Canine assisted
RxNorm normalized name: CanineAid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canine assisted occupational therapy (n=11)
Trial: 32266682
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy sessions as usual (waitlist control group, n=11)
Trial: 35483209
Drug: ALIMFUS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALIMFUS therapy for 10 minutes on alternate days for 90 days
Trial: 35483209
Drug: ALIMFUS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALIMFUS therapy
Trial: 35922010
Drug: Closed Treatment
RxNorm normalized name: Closed Pouch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed Treatment (CT)
Trial: 35381064
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at optimal dose of 160 mg/m2 during concurrent phase
Trial: 35381064
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at optimal dose of 260 mg/m2 during induction/adjuvant phase
Trial: 35381064
Drug: Cisplatin throughout
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin throughout treatment (no replacement by carboplatin)